[Oral contraceptives and endometrial and ovarian carcinomas].
Combined oral contraceptives reduce the risk of endometrial and ovarian cancer by about 50%. The risk of both carcinomas decreases with an increasing duration of oral contraceptive use. The reduced risk lasts for 10-15 years after cessation. A significantly lower risk of developing an endometrial carcinoma can be observed for contraceptives with a high progestin and a low estrogen concentration. Due to the protective effect, the use of oral contraceptives is a useful means for primary prevention (chemoprevention) in women at high risk of endometrial and ovarian cancers.
Medl
M
M
Gynäkologisch-geburtshilfliche Abteilung, Krankenhaus Lainz, Wien, Osterreich.
D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D016889:Endometrial Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000517:prevention & control*; D012306:Risk
D003277:Contraceptives, Oral, Combined